Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021 at 04:04 pm EDT
Share
Relmada Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 26.461 million compared to USD 12.757 million a year ago. Net loss was USD 26.551 million compared to USD 11.118 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 0.73 a year ago. For the half year, operating loss was USD 48.867 million compared to USD 22.731 million a year ago. Net loss was USD 48.767 million compared to USD 21.791 million a year ago. Basic loss per share from continuing operations was USD 2.9 compared to USD 1.45 a year ago.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
RELMADA THERAPEUTICS, INC. 
